How to submit ICSRs and SUSARs to the MHRA if the UK leaves the EU with no-deal

The Medicines and Healthcare products Regulatory Agency (MHRA) has released guidance for all pharmaceutical companies involved in the submission of Individual Case Safety Reports (ICSRs) or Suspected Unexpected Serious Adverse Reactions (SUSARs) in the event of a no-deal Brexit. Read more “How to submit ICSRs and SUSARs to the MHRA if the UK leaves the EU with no-deal”

Regulis attends 18th Pharmacovigilance 2019 conference

The Regulis Pharmacovigilance team were delighted to attend and exhibit at the 18th Annual Pharmacovigilance 2019 in London last month.  Senior Pharmacovigilance Executive Pavan Bamrah said “we had a great couple of days with thought-provoking presentations and lots of interesting conversations with colleagues”. Read more “Regulis attends 18th Pharmacovigilance 2019 conference”

ABPI revises guidance for Pharmacovigilance in Market Research

The Association of the British Pharmaceutical Industry (ABPI) and the British Healthcare Business Intelligence Association (BHBIA) have produced a revised version of their guidance on collecting adverse events, product complaints and special situation reports during market research programmes (MRPs). The guidance document was first issued in October 2009, and is now version 4, which took effect from the beginning of October 2018. Read more “ABPI revises guidance for Pharmacovigilance in Market Research”

TGA opens consultation on use of boxed warnings to highlight safety issues

The Therapeutic Goods Administration (TGA) Australia has opened a consultation on guidance regarding the use of boxed warnings used to highlight serious safety issues. The guidance outlines the objectives for introducing a boxed warning to a Product Information (PI) document, and provides advice on how and when to use a boxed warning. The aim is to ensure consistency across the prescription medicines regulatory framework. Read more “TGA opens consultation on use of boxed warnings to highlight safety issues”

EMA clarifies MAH obligations to record adverse events accessed through EudraVigilance

The European Medicines Agency (EMA) has published a note which clarifies the pharmacovigilance obligations of marketing authorisation holders (MAHs). The note provides information about when MAHs must record information regarding adverse events they access via EudraVigilance. Read more “EMA clarifies MAH obligations to record adverse events accessed through EudraVigilance”

EMA publishes updated Q&A from stakeholders on the launch of the new EudraVigilance system

The European Medicines Agency (EMA) has published an updated question and answer (Q&A) document from stakeholders on the launch of the new EudraVigilance system. The document addresses questions that were received from stakeholders as part of the launch of the new EudraVigilance system, which went live on 22nd November 2017. Read more “EMA publishes updated Q&A from stakeholders on the launch of the new EudraVigilance system”